Previous 10 | Next 10 |
home / stock / lexxw / lexxw news
(TheNewswire) Kelowna, B C - TheNewswire - April 20, 2023 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms announces that it has...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its diabetes animal model study DIAB-A22-1 has completed and produced at least three positive outcomes including weight loss in obese diabetic-conditioned animals, together with improved...
(TheNewswire) Kelowna, British Columbia – TheNewswire - March 2, 2023 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that its diabetes ani...
KELOWNA, BC / ACCESSWIRE / February 21, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW ) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce additional findings from its human clinical study HYPER-H21-4 ("the Study") demonstrati...
(TheNewswire) Kelowna, British Columbia – TheNewswire - February 21, 2023 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce ...
(TheNewswire) Kelowna, BC - TheNewswire - January 23, 2023 - Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that the former P...
(TheNewswire) Kelowna, B C - TheNewswire - January 13, 2023 - Lexaria Bioscience Corp. ( XNAS :LEXX) ( XNAS :LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provi...
KELOWNA, BC / ACCESSWIRE / January 13, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide an annual letter from CEO, Chris Bunka and a thorough strategic update to all stakeholders. CEO ...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. According to the update, Can...
KELOWNA, BC / ACCESSWIRE / December 29, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce its continued accumulation of international patent recognition with the receipt of its first gran...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Warrant Website:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects ...